Last reviewed · How we verify

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. pipeline: 3 marketed, 0 filed, 14 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 14 Phase 3 7 Phase 2 25 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
400mg 400mg marketed
Sandostatin ® injection Sandostatin ® injection marketed Somatostatin analog Somatostatin receptors (SSTR2, SSTR5) Oncology; Endocrinology
200mg 200mg marketed Nonsteroidal Anti-inflammatory Drug [EPC]
SYS6002 SYS6002 phase 3
DBPR108; Placebo matching sitagliptin DBPR108; Placebo matching sitagliptin phase 3 DPP-4 inhibitor (sitagliptin reference) DPP-4 (dipeptidyl peptidase-4) Diabetes
SYSA1901 SYSA1901 phase 3 PD-1 inhibitor PD-1 Oncology
semaglutide injection (HD1916) semaglutide injection (HD1916) phase 3 GLP-1 receptor agonist GLP-1R Diabetes
Hydroxocobalamin Chloride Injection Hydroxocobalamin Chloride Injection phase 3 Vitamin B12 (cobalamin) supplement Cobalamin-dependent enzymes (methionine synthase, methylmalonyl-CoA mutase) Hematology / Nutritional deficiency
SKLB1028 SKLB1028 phase 3 Multi-kinase inhibitor Oncology
Salvage Chemotherapy Salvage Chemotherapy phase 3 Oncology
Amphotericin B liposomes Amphotericin B liposomes phase 3 Polyene antifungal Ergosterol Infectious Disease
Placebo matching DBPR108; Sitagliptin; DBPR108 Placebo matching DBPR108; Sitagliptin; DBPR108 phase 3 DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4) Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 6 shared drug classes
  2. Sanofi · 5 shared drug classes
  3. Daewoong Pharmaceutical Co. LTD. · 4 shared drug classes
  4. HK inno.N Corporation · 3 shared drug classes
  5. GlaxoSmithKline · 3 shared drug classes
  6. AstraZeneca · 3 shared drug classes
  7. CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 3 shared drug classes
  8. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for CSPC ZhongQi Pharmaceutical Technology Co., Ltd.:

Cite this brief

Drug Landscape (2026). CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cspc-zhongqi-pharmaceutical-technology-co-ltd. Accessed 2026-05-16.

Related